WO2021208336A1 - 中药组合物及其应用 - Google Patents

中药组合物及其应用 Download PDF

Info

Publication number
WO2021208336A1
WO2021208336A1 PCT/CN2020/113275 CN2020113275W WO2021208336A1 WO 2021208336 A1 WO2021208336 A1 WO 2021208336A1 CN 2020113275 W CN2020113275 W CN 2020113275W WO 2021208336 A1 WO2021208336 A1 WO 2021208336A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
chinese medicine
traditional chinese
medicine composition
asymptomatic
Prior art date
Application number
PCT/CN2020/113275
Other languages
English (en)
French (fr)
Inventor
张忠德
邹旭
金连顺
唐丽娟
王媛媛
刘云涛
奚小土
丁邦晗
杨荣源
Original Assignee
广东省中医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东省中医院 filed Critical 广东省中医院
Publication of WO2021208336A1 publication Critical patent/WO2021208336A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the invention belongs to the technical field of traditional Chinese medicine, and relates to a traditional Chinese medicine composition for anti-virus and its application.
  • Chinese patent application CN1480194A discloses an anti-SARS virus oral liquid, which includes Eucalyptus grandiflora, honeysuckle, green leaf, artemisia annua, houttuynia cordata, isatis root, ganmei, wild chrysanthemum, peppermint, Guanzhong, Forsythia, Atractylodes Rhizome, Huang Cen, the medicine clears away heat and toxins, relieves fever and dampness, relieves the pharynx, relieves cough and promotes the lungs, and can prevent and treat SARS virus, influenza virus and common cold virus.
  • Chinese patent application CN101703606A discloses an oral liquid for preventing diseases and avoiding epidemics. Its raw materials are composed of atractylodes, wormwood, arborvitae leaves, pepper, peach kernel, mint, perilla, honeysuckle, platycodon, ebony, raw licorice, vitamin C, Honey.
  • Chinese patent application CN104383041A discloses a Chinese medicinal composition for the treatment of viral lung injury caused by H1N1 influenza, including ganmei root, patchouli, Qianghuo, Bupleurum, safflower, honeysuckle, fangfeng, nepeta, forsythia, and atractylodes , Peach kernels and artificial bezoars have the functions of permeating pathogens, detoxifying the lungs, resolving phlegm and removing blood stasis, etc., and can be used to treat viral lung injury caused by H1N1 influenza.
  • the above three existing technologies are all antiviral drugs, they all start with detoxification and lung expansion, acting on the body in the form of oral administration, regulating the body with multiple targets, and adjusting the internal conditions of the body to improve the virus's influence on the body and reduce the body. Viral load, long treatment cycle, and oral administration will also produce certain irritation to the gastrointestinal tract.
  • the new coronavirus and SARS coronavirus are of the same type, but not the same kind, and are very different from H1N1 influenza. Whether the drugs in the above patent application can be used to treat the new coronavirus remains to be determined.
  • the virus mostly gathers in the nose, mouth, and throat, but the above-mentioned existing technologies are not highly targeted for viruses that gather in the nose, mouth, and throat.
  • a traditional Chinese medicine composition for anti-virus which comprises the following components in parts by mass: 25-35 parts of gangme root, 5-10 parts of peppermint, 15-25 parts of ebony plum, and Atractylodes macrocephala 10-20 servings.
  • Atractylodes lavandulata is responsible for calming the stomach and invigorating the spleen, widening the masses, sweating and dispelling dampness, suppressing the hills and hills, and dissipating temperature and maltreatment.
  • Peppermint has a pungent taste, clear qi and fragrant, it can relieve wind and throat, help atractylodes evacuate external evil, as an adjuvant;
  • the whole prescription is used in combination with cold and heat, aroma addiction does not help heat, sour and sweet, but not depressed.
  • the traditional Chinese medicine composition of the present invention takes the oral cavity as the main disease site and acts on the throat as a supplement, and aims at the characteristic that the virus of SARS-CoV-2 asymptomatic infection is mostly concentrated in the nose, mouth, and throat.
  • the drug directly acts on the virus, which is beneficial to eliminate the virus more quickly, stifle the virus in the mouth and throat, prevent the virus from entering the lungs and cause aggravation, and provide treatment for patients with asymptomatic SARS-CoV-2 infection.
  • An effective drug plan to meet the urgent need for treatment of asymptomatic infections and to improve the existing diagnosis and treatment plan.
  • Gangmei root which is the root of the holly family plant plum leaf holly, has the effects of clearing heat, promoting body fluid, invigorating blood, and detoxifying.
  • Peppermint is the dry aerial part of Mentha haplocalyx Briq., a plant of the genus Lamiaceae. It has the effects of dispersing wind, heat dissipation, filth and detoxification.
  • Black plum is the dry and nearly mature fruit of Prunus mume (Sieh.) Sieb. et Zucc.
  • Atractylodes is the dried rhizome of Atractylodes lancea (Thunb.) DC. or Atractylodes chinensis (DC.) Koidz. of the Compositae family.
  • the traditional Chinese medicine composition may preferably include the following components in parts by mass: 30-35 parts of ganmei root, 8-12 parts of peppermint, 15-20 parts of ebony, 15-20 parts of atractylodes; it can be further preferred It is: 30 parts of gangme root, 10 parts of mint, 20 parts of ebony plum and 15 parts of Ctractylodes.
  • a medicine containing the above-mentioned traditional Chinese medicine composition which may include medically acceptable additives and/or excipients.
  • the above-mentioned traditional Chinese medicine composition or medicine can be prepared by using existing traditional Chinese medicine preparations, taking the traditional Chinese medicine composition as the main active ingredient, and adding medically acceptable additives and/or excipients. , Into any conventional pharmaceutical form, such as: gargle or spray and other dosage forms.
  • additives or excipients commonly used in the art can be used.
  • Additives can be flavoring agents, thickeners or preservatives.
  • the flavoring agents include but are not limited to aspartame and xylitol. , Steviol, sodium saccharin, food flavors, etc.
  • Thickeners include but are not limited to hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, acacia, pectin or sodium alginate, etc.
  • Preservatives include but are not limited to Potassium sorbate, ethyl p-hydroxybenzoate or sodium benzoate, etc.
  • the traditional Chinese medicine composition is a gargle, it can be prepared by the following existing methods:
  • the raw material components of the Chinese medicine composition are decocted for 1-2h with 6-10 times the total mass of the raw material medicine, and extracted for more than 2 times.
  • the extracts are combined, filtered, concentrated, and additives are added. After fully stirring and dissolving, add water to a sufficient amount , Mix well, let stand for more than 24h, then filter, the filtrate obtained is the gargle.
  • the traditional Chinese medicine composition is a spray
  • it can be prepared by the following method: Obtain the filtrate according to the method of preparing the gargle as described above, and fill the filtrate into a spray-generating device.
  • the administration method of the traditional Chinese medicine composition of the present invention is only a mouthwash or a throat spray for external use, and does not require oral administration to prevent oral irritation to the gastrointestinal tract and avoid damage to liver and kidney functions through liver and kidney metabolism, and has high safety.
  • the application of the above-mentioned traditional Chinese medicine composition or medicine in the preparation of medicines for treating asymptomatic viral infections Specifically, it can be used in the preparation of drugs for treating SARS-CoV-2 asymptomatic infection cases.
  • the traditional Chinese medicine composition or medicine of the present invention can also be used as a medicine for treating viral colds or influenza, mainly for symptoms such as fever, cough, sore throat, itchy throat, dry throat, hoarseness, fatigue and other symptoms caused by influenza.
  • the traditional Chinese medicine composition or medicine of the present invention can also be used as a medicine for the treatment of acute upper respiratory tract infections (such as the common cold, viral pharyngitis, laryngitis, herpes angina, etc.) and chronic pharyngitis.
  • acute upper respiratory tract infections such as the common cold, viral pharyngitis, laryngitis, herpes angina, etc.
  • chronic pharyngitis caused by dry throat, itchy throat, sore throat, hoarseness and other symptoms can also improve.
  • the traditional Chinese medicine composition of the present invention When used for the treatment of SARS-CoV-2 asymptomatic infection cases, it can be given to asymptomatic infected persons one dose per day (may be: gangme root 30g, peppermint 10g, ebony 20g, atractylodes 15g), divided into four Gargle or spray your throat once, gargle for 1-3 minutes each time, and use it for 14 days.
  • asymptomatic infections refer to: no relevant clinical manifestations, such as fever, cough, pharynx Those who have self-perceived or clinically recognizable symptoms and signs, such as pain, but the respiratory tract and other specimens have tested positive for the pathogen of the new coronavirus.
  • asymptomatic infections There are two situations for asymptomatic infections: one is that they have no self-perceived or clinically recognizable symptoms and signs after 14 days of quarantine medical observation; the other is the state of "asymptomatic infection" in the incubation period.
  • the antiviral Chinese medicine composition is prepared from the following components: 30 g of ganmei root, 10 g of peppermint, 20 g of ebony plum, and 15 g of atractylodes.
  • the raw material components of the Chinese medicine composition are decocted for 2 hours with 10 times the total mass of the raw material medicine, and extracted twice, the extracts are combined, filtered, concentrated, flavoring agents, thickeners, and preservatives are added, and after fully stirring and dissolving, Add water to a sufficient amount, mix well, let it stand for more than 24 hours, and then filter.
  • the filtrate obtained is a gargle.
  • the antiviral Chinese medicine composition is prepared from the following components: 30 g of ganmei root, 10 g of peppermint, 20 g of ebony plum, and 15 g of atractylodes.
  • the antiviral Chinese medicine composition is prepared from the following components: 35 g of ganmei root, 10 g of peppermint, 25 g of ebony plum, and 15 g of atractylodes.
  • a traditional Chinese medicine composition used for anti-virus is prepared from the following components: 30 g of ganmei root, 5 g of peppermint, 15 g of ebony plum, and 10 g of atractylodes rhizome.
  • a traditional Chinese medicine composition for anti-virus is prepared from the following components: 25 g of ganmei root, 8 g of peppermint, 15 g of ebony plum, and 15 g of atractylodes rhizome.
  • the traditional Chinese medicine composition of the present invention can be well used for the treatment of patients with asymptomatic SARS-CoV-2 infection, improve the negative rate of pathogenic detection of new coronavirus in specimens such as respiratory tract, and reduce the ratio of asymptomatic infections to new coronary pneumonia. Because of:
  • SARS-CoV-2 asymptomatic infection belongs to the category of "epidemic disease” in traditional Chinese medicine. Its disease is caused by the exposure of the epidemic virus and the dampness of the Lingnan area. The gas phase is transmitted, because the righteousness is still strong, and the symptoms such as fever, asthma, chest suffocation, palpitations, diarrhea, fatigue, etc. are not manifested. If the righteous qi is insufficient and the qi of the epidemic disease invades the lungs and stomach, the condition may worsen during the observation and isolation period and develop new coronary pneumonia.
  • the traditional Chinese medicine composition of the present invention takes the oral cavity as the main disease site and acts on the throat as a supplement, and is aimed at the characteristics that the virus of SARS-CoV-2 asymptomatic infection is mostly concentrated in the nose, mouth, and throat.
  • an effective drug program is provided for the treatment of asymptomatic SARS-CoV-2 infections, to meet the current urgent needs for the treatment of asymptomatic infections, and to improve the existing diagnosis and treatment programs.
  • the invented Chinese medicinal composition can prevent the deterioration of the disease through sour and sweet production of body fluid, and at the same time, through nourishing yin, promoting body fluid, promoting blood circulation, invigorating the spleen to strengthen the body, replenish the deficiency of qi, clear away heat and detoxify to drive away evil spirits, and prevent transmission of changes.
  • the present invention also improves symptoms such as influenza, acute upper respiratory tract infection (common cold, viral pharyngitis, laryngitis, herpetic angina, etc.), chronic pharyngitis, such as dry throat, itchy throat, sore throat, hoarseness, etc. effect.
  • acute upper respiratory tract infection common cold, viral pharyngitis, laryngitis, herpetic angina, etc.
  • chronic pharyngitis such as dry throat, itchy throat, sore throat, hoarseness, etc. effect.
  • the drug administration route of the present invention is only to gargle or spray the throat for external use, and does not need to be taken orally, which prevents oral irritation to the gastrointestinal tract, avoids damage to liver and kidney functions through liver and kidney metabolism, and has high safety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种中药组合物及其在制备治疗病毒性，特别是SARS-CoV-2无症状感染病例、流行性感冒、急性上呼吸道感染、慢性咽炎的药物中的应用，所述中药组合物以质量份计包括：岗梅根25-35、薄荷5-10、乌梅15-25、苍术10-20。

Description

中药组合物及其应用 技术领域
本发明属于中药技术领域，涉及一种用于抗病毒的中药组合物及其应用。
背景技术
2019年12月以来，新型冠状病毒(SARS-CoV-2)已致多人感染并导致新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)，但还存在一部分新冠病毒无症状感染者(以下简称无症状感染者)，这部分无症状感染者无相关临床表现，如发热、咳嗽、咽痛等可自我感知或可临床识别的症状与体征，但呼吸道等标本新冠病毒病原学检测呈阳性者。虽然国内新冠肺炎疫情基本上已受控，但无症状感染者越来越多，而无症状感染者具有高度传染性，以及具有较大转归为新型冠状病毒肺炎的可能性，由此，针对无症状感染者的筛查与药物干预显得十分重要和紧迫。
中国专利申请CN1480194A公开了一种抗“非典”病毒口服液，该口服液包括大叶桉、金银花、大青叶、青蒿、鱼腥草、板蓝根、岗梅、野菊花、薄荷、贯众、连翘、苍术、黄岑，该药清热解毒、退热祛湿、利咽止咳宣肺，可预防和治疗“非典”病毒及流感型病毒和普通感冒病毒。
中国专利申请CN101703606A公开了一种防病避疫的口服液，其原料组成为：苍术、艾、侧柏叶、花椒、桃仁、薄荷、紫苏、金银花、桔梗、乌梅、生甘草、维生素C、蜂蜜。
中国专利申请CN104383041A公开了一种治疗H1N1流感引起的病毒性肺损伤的中药组合物，包括岗梅根、广藿香、羌活、柴胡、红花、金银花、防风、荆芥、连翘、苍术、桃仁以及人工牛黄，具有透邪解表，解毒宣肺，化痰祛瘀等作用，可用于治疗H1N1流感引起的病毒性肺损伤。
上述三份现有技术虽然都是抗病毒药物，但均从解毒宣肺着手，以内服形式作用于机体，对机体进行多靶点调节，通过调节机体内部情况来改善病毒对机体影响，降低体内病毒载量，治疗周期长，通过内服对胃肠道也会产生一定的刺激。此外，新型冠状病毒与SARS冠状病毒是同一类，但不是同一种，与H1N1流感更是存在很大的差异，上述专利申请的药物是否能用于治疗新型冠状病毒，有待考究。而且，对于新型冠状病毒无症状感染者，病毒多聚集于鼻、口、咽喉部，但上述现有技术对于聚集于鼻、口、咽喉部的病毒针对性都不强。
发明内容
根据本发明的一个方面，提供了一种用于抗病毒的中药组合物，以质量份 计包括如下组分：岗梅根25-35份，薄荷5-10份，乌梅15-25份，苍术10-20份。
方中：
以岭南道地药材岗梅根为君药，可清热、生津、解毒；
苍术主平胃健脾、宽中散结、发汗祛湿、压山岗气、散温虐，故以苍术为臣药，燥湿解毒；
薄荷味辛，气清郁香窜，可疏风利咽，助苍术疏散外邪，为佐药；
乌梅为使，酸收养阴利咽，防苍术、薄荷辛散太过。
全方寒热并用，芳香癖秽而不助热，酸甘生津而不郁遏。
本发明的中药组合物以口腔为主要的病位作用点，辅以作用于咽喉，针对SARS-CoV-2无症状感染者的病毒多聚集于鼻、口、咽喉部的特点，通过酸甘化津、芳香癖秽，药物直接作用于病毒，有利于更快清除病毒，将病毒扼杀在口腔、咽喉部，防止病毒进入肺部造成病情加重，为SARS-CoV-2无症状感染者治疗提供了一个有效的药物方案，以满足现在对无症状感染者治疗手段的迫切需求，以及完善现有的诊疗方案。
具体地：
岗梅根，为冬青科植物梅叶冬青的根，具有清热、生津、活血、解毒之功效。
薄荷，为唇形科薄荷属植物薄荷Mentha haplocalyx Briq.的干燥地上部分，具有疏风、散热、辟秽、解毒之功效。
乌梅，为蔷薇科植物梅Prunus mume(Sieh.)Sieb.et Zucc.的干燥近成熟果实，具有敛肺、涩肠、生津之功效。
苍术，为菊科植物茅苍术Atractylodes lancea(Thunb.)DC.或北苍术Atractylodes chinensis(DC.)Koidz.的干燥根茎，具有燥湿健脾、祛风散寒之功效。
在一些实施方式中，中药组合物以质量份计可以优选包括如下组分：岗梅根30-35份，薄荷8-12份，乌梅15-20份，苍术15-20份；还可以进一步优选为：岗梅根30份，薄荷10份，乌梅20份，苍术15份。
根据本发明的一个方面，提供了一种含有上述中药组合物的药物，该药物组合物可以包括医学上可接受的添加剂和/或赋形剂。
在一些实施方式中，为了方便临床给药，上述中药组合物或药物可以利用现有中药制剂制备方法，以中药组合物为主要活性成分，通过加入医学上可接受的添加剂和/或赋形剂，做成任何常规的药物形式，如：含漱剂或喷雾剂等剂型。
例如，添加剂或赋形剂可采用本领域常用的添加剂或赋形剂，添加剂可以为矫味剂、增稠剂或防腐剂，其中，矫味剂包括但不限于阿斯巴甜、木糖醇、 甜菊素、糖精钠、食用香精等，增稠剂包括但不限于羟丙基甲基纤维素、羧甲基纤维素钠、阿拉伯胶、果胶或海藻酸钠等，防腐剂包括但不限于山梨酸钾、对羟基苯甲酸乙酯或苯甲酸钠等。由此，以帮助提高药物组合物的稳定性或提高活性，或在口服情况下产生可接受的口感或气味。
不同的药物剂型，可以根据现有技术制备得到，示例性地：
当中药组合物为含漱剂时，可采取下述现有方法制备得到：
将中药组合物的原料组分加原料药总质量6-10倍的水煎煮1-2h，提取2次以上，合并提取液，过滤，浓缩，加入添加剂，充分搅拌溶解后，加水至足量，混匀，静置24h以上，然后过滤，得到的滤液即为含漱剂。
当中药组合物为喷雾剂时，可采取下述方法制备得到：根据上述制备含漱剂的方法获得滤液，将滤液填充至能产生喷雾的装置中即可。
应该说明的是，上述喷雾剂的制备方式只是示例性的，并不对本发明所保护的范围做限制，当然，为了制备该喷雾剂药物，还可以采用本领域通常使用技术，在此不一一举出。
此外，本发明的中药组合物给药方式仅仅是外用漱口或喷喉，不用口服，防止口服对胃肠道的刺激，避免通过肝肾代谢对肝肾功能等的损害，安全性高。
根据本发明的另一个方面，提供了上述中药组合物或药物在制备治疗病毒性无症状感染病例药物中的应用。具体地，可以是在制备治疗SARS-CoV-2无症状感染病例药物中的应用。
本发明的中药组合物或药物还可以用作治疗病毒性感冒或流感药物使用，主要针对由流行性感冒所导致的发热、咳嗽、咽痛、咽痒、咽干、声音嘶哑、乏力等症状。
此外，本发明的中药组合物或药物还可以作为治疗急性上呼吸道感染(如普通感冒、病毒性咽炎、喉炎、疱疹性咽峡炎等)、慢性咽炎的药物使用，其对急性上呼吸道感染(如普通感冒、病毒性咽炎、喉炎、疱疹性咽峡炎等)、慢性咽炎所导致的咽干、咽痒、咽痛、声音嘶哑等症状也有改善作用。
本发明的中药组合物用于SARS-CoV-2无症状感染病例治疗时，可以给予无症状感染者每天一剂(可以是：岗梅根30g，薄荷10g，乌梅20g，苍术15g)，分四次含漱或喷喉，每次漱口1-3分钟，连用14天。
具体实施方式
下面结合具体实施例对本发明作进一步详细的说明。值得说明的是，本发明中“无症状感染者”“SARS-CoV-2无症状感染者”“SARS-CoV-2无症状感染病例”是指：无相关临床表现，如发热、咳嗽、咽痛等可自我感知或可临床识别 的症状与体征，但呼吸道等标本新冠病毒病原学检测呈阳性者。
无症状感染者有两种情形：一是经14天的隔离医学观察，均无任何可自我感知或可临床识别的症状与体征；二是处于潜伏期的“无症状感染”状态。
本发明的药物不同剂型制备方法中未写入的内容，均被现有技术公开，应视为本领域的公知常识。
实施例1
用于抗病毒的中药组合物，由以下组分制备得到：岗梅根30g，薄荷10g，乌梅20g，苍术15g。
取上述组分，根据如下现有方法制备得到含漱剂：
将中药组合物的原料组分加原料药总质量10倍的水煎煮2h，提取2次，合并提取液，过滤，浓缩，加入矫味剂、增稠剂、防腐剂，充分搅拌溶解后，加水至足量，混匀，静置24h以上，然后过滤，得到的滤液即为含漱剂。
实施例2
用于抗病毒的中药组合物，由以下组分制备得到：岗梅根30g，薄荷10g，乌梅20g，苍术15g。
取上述组分，根据实施例1制备含漱剂的方法获得滤液，将滤液填充至能产生喷雾的装置，即得到喷雾剂。
实施例3
用于抗病毒的中药组合物，由以下组分制备得到：岗梅根35g，薄荷10g，乌梅25g，苍术15g。
取上述组分，根据实施例1的方法，得到含漱剂。
实施例4
用于抗病毒的中药组合物，由以下组分制备得到：岗梅根30g，薄荷5g，乌梅15g，苍术10g。
取上述组分，根据实施例1的方法，得到含漱剂。
实施例5
用于抗病毒的中药组合物，由以下组分制备得到：岗梅根25g，薄荷8g，乌梅15g，苍术15g。
取上述组分，根据实施例1的方法，得到含漱剂。
本发明的中药组合物可以很好地用于SARS-CoV-2无症状感染者的治疗，提 高呼吸道等标本新冠病毒病原学检测转阴率，降低无症状感染者转为新冠肺炎的比例，这是因为：
SARS-CoV-2无症状感染，属于中医学“疫病”的范畴，其病因为感受疫毒，加之岭南地区潮湿，形成湿毒疫疠之气，从口鼻咽喉而入，涉及肺胃，疫气相传，因正气尚强，未表现出发热、气喘、胸憋、心悸、腹泻、乏力等症状。若正气不足，外感疫疠之气，侵袭肺胃，则可在观察隔离期间病情加重，发展为新冠肺炎。
因此，本发明的中药组合物，一方面以口腔为主要的病位作用点，辅以作用于咽喉，针对SARS-CoV-2无症状感染者的病毒多聚集于鼻、口、咽喉部的特点，通过酸甘化津、芳香癖秽，将药物直接作用于病毒，有利于更快清除病毒，将病毒扼杀在口腔、咽喉部，防止病毒进入肺部造成病情加重，减小由无症状感染转变为新冠肺炎的概率，为SARS-CoV-2无症状感染者治疗提供了一个有效的药物方案，以满足现在对无症状感染者治疗手段的迫切需求，并完善了现有的诊疗方案。
另一方面，在病毒特别是SARS-CoV-2感染后，机体病邪内羁，气血津液受耗，还可能会出现“津液为火灼竭，则血行愈滞”的情形，因此，本发明的中药组合物通过酸甘生津，以阻止病情恶化，同时，通过养阴、生津、活血、健脾以扶正、补正气之不足，清热、解毒以驱邪，双管齐下，防止传变。
本发明对流行性感冒、急性上呼吸道感染(普通感冒、病毒性咽炎、喉炎、疱疹性咽峡炎等)、慢性咽炎所导致的咽干、咽痒、咽痛、声音嘶哑等症状也有改善作用。
本发明的药物给药途径仅仅是外用漱口或喷喉，不用口服，防止口服对胃肠道的刺激，避免通过肝肾代谢对肝肾功能等的损害，安全性高。
以上所述的仅是本发明的一些实施方式。对于本领域的普通技术人员来说，在不脱离本发明创造构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。

Claims (11)

  1. 中药组合物，其特征在于，以质量份计包括如下组分：岗梅根25-35份，薄荷5-10份，乌梅15-25份，苍术10-20份。
  2. 根据权利要求1所述的中药组合物，其特征在于，以质量份计包括如下组分：岗梅根30-35份，薄荷6-10份，乌梅15-20份，苍术15-20份。
  3. 根据权利要求1所述的中药组合物，其特征在于，以质量份计包括如下组分：岗梅根30份，薄荷10份，乌梅20份，苍术15份。
  4. 包括权利要求1-3任一项所述的中药组合物的药物，其特征在于，还包括医学上可接受的添加剂和/或赋形剂。
  5. 根据权利要求4所述的药物，其特征在于，所述药物为含漱剂或喷雾剂。
  6. 权利要求1-3任一项所述的中药组合物在制备治疗病毒性无症状感染病例药物中的应用。
  7. 根据权利要求6所述的应用，其特征在于，所述病毒性无症状感染病例包括SARS-CoV-2无症状感染病例。
  8. 权利要求5所述的药物在制备治疗病毒性无症状感染病例药物中的应用。
  9. 根据权利要求8所述的应用，其特征在于，所述病毒性无症状感染病例包括SARS-CoV-2无症状感染病例。
  10. 权利要求1-3任一项所述的中药组合物在制备治疗流行性感冒、急性上呼吸道感染、慢性咽炎中的应用。
  11. 权利要求5所述的药物在制备治疗流行性感冒、急性上呼吸道感染、慢性咽炎药物中的应用。
PCT/CN2020/113275 2020-04-16 2020-09-03 中药组合物及其应用 WO2021208336A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010300884.8A CN111481593A (zh) 2020-04-16 2020-04-16 中药组合物及其应用
CN202010300884.8 2020-04-16

Publications (1)

Publication Number Publication Date
WO2021208336A1 true WO2021208336A1 (zh) 2021-10-21

Family

ID=71789873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/113275 WO2021208336A1 (zh) 2020-04-16 2020-09-03 中药组合物及其应用

Country Status (2)

Country Link
CN (1) CN111481593A (zh)
WO (1) WO2021208336A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111481593A (zh) * 2020-04-16 2020-08-04 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 中药组合物及其应用
KR102640518B1 (ko) * 2020-12-11 2024-02-27 숙명여자대학교산학협력단 프루누스 속 식물의 추출물을 포함하는 항-코로나 바이러스용 조성물
CN115814049B (zh) * 2022-12-12 2024-05-07 北京博奥晶方生物科技有限公司 中药组合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104258116A (zh) * 2014-09-06 2015-01-07 扬中牧乐药业有限公司 一种治疗病毒性感冒的口服液
CN111481593A (zh) * 2020-04-16 2020-08-04 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 中药组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1082885A (zh) * 1992-08-22 1994-03-02 张承德 中国药物清洁防感保健香精
CN100594031C (zh) * 2005-12-29 2010-03-17 株洲千金药业股份有限公司 一种含片及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104258116A (zh) * 2014-09-06 2015-01-07 扬中牧乐药业有限公司 一种治疗病毒性感冒的口服液
CN111481593A (zh) * 2020-04-16 2020-08-04 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 中药组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEN JIE; ZHENG MINXIA; XIE SHENGYANG; SUN CAIHUA: "Composition Ｒegularities of Chinese Materia Medica Formulas for the Coronavirus Disease 2019", CHINA PHARMACEUTICALS, vol. 29, no. 6, 20 March 2020 (2020-03-20), pages 25 - 28, XP055859986 *

Also Published As

Publication number Publication date
CN111481593A (zh) 2020-08-04

Similar Documents

Publication Publication Date Title
Lee et al. Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis
JP5336656B2 (ja) 気管支炎を治療するための麻黄含有医薬組成物およびその調製方法
WO2021208336A1 (zh) 中药组合物及其应用
CN111265616B (zh) 一种中药组合物及其在病毒性肺炎防治方面的应用
WO2021208335A1 (zh) 解毒化湿利咽中药组合物及其应用
WO2021227614A1 (zh) 一种用于清肺化纤的药物组合物及其用途
WO2021179505A1 (zh) 一种翘芪复方制剂及其制备方法和用途
CN102657804B (zh) 一种治疗病毒性感冒的中药组合物及其制备方法
Kalra et al. Cold and flu: conventional vs. botanical and nutritional therapy
CN104353029A (zh) 一种润肺橘红膏及其制备方法
WO2023125798A1 (zh) 一种中药组合物及其制备方法和应用
CN105381153A (zh) 治疗支气管炎的中药制剂及制备方法
CN101380411A (zh) 止咳化痰的中药制剂
CN111407808B (zh) 一种中药组合物及其制备方法与制药应用
CN103405722B (zh) 一种预防和治疗小儿咳嗽的中药制剂
WO2021103777A1 (zh) 一种用于儿童、青少年过敏性哮喘合并过敏性鼻炎防治的喷雾剂
CN105833034A (zh) 一种治疗哮喘的中药组合物
CN105963501A (zh) 一种制备治疗小儿哮喘的中药组合物的方法
CN1322884C (zh) 治疗慢性支气管炎胶囊及其制备工艺
US11998583B2 (en) Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof
RU2810482C1 (ru) Лекарственная композиция ТКМ и её применение в профилактике и лечении вирусной пневмонии
CN114917287B (zh) 一种治疗过敏性哮喘的中药组合物，其制备方法和应用
CN108815329A (zh) 一种治疗感冒的中药组合物及其制备方法
CN115624586B (zh) 一种治疗激素依赖性哮喘的中药组合物以及应用
CN101385825B (zh) 一种防治感冒的中药制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20930731

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20930731

Country of ref document: EP

Kind code of ref document: A1